Physician profile
Michael J Smith
NPI 1740240076
$7,721.03
in general payments reported to CMS, 2019-2025
45 companies · $1,078 in 2025
The $1,078 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2020: $894 · 2021: $1,401 · 2022: $1,290 · 2023: $1,279 · 2024: $1,122 · 2025: $1,078.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,447 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,446.75 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,051.56 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $985.61 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $856.58 | 2020-2025 | Synjardy, Jardiance, Tradjenta |
| Abbvie INC. | $819.28 | 2019-2025 | Linzess, Creon, Viberzi |
| Astrazeneca Pharmaceuticals Lp | $805.90 | 2019-2023 | Farxiga |
| Pfizer INC. | $419.96 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $373.84 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $293.70 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $230.11 | 2020-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Amgen INC. | $200.04 | 2019-2024 | Prolia, Evenity |
| Dexcom, INC. | $198.96 | 2022-2023 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $134.53 | 2019-2025 | Bexsero, Shingrix, Arexvy |
| Novartis Pharmaceuticals Corporation | $133.65 | 2019-2024 | |
| Janssen Biotech, INC. | $109.68 | 2023-2025 | Stelara, Tremfya, Remicade |
| Genzyme Corporation | $105.20 | 2025 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.